BNP/CALL/ASTRAZENECA/15000/0.1/19.12.25 Stock

BNP/CALL/ASTRAZENECA/15000/0.1/19.12.25 Share Price

DE000PC836J8

Market Closed - Boerse Frankfurt Warrants 08:51:12 14/06/2024 pm IST
1.13 ^EUR	+5.61%

Current month	+22.83%
1 month	+21.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/15000/0.1/19.12.25

Latest news about ASTRAZENECA PLC

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	16/06	BU
AstraZeneca : Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	16/06	PU
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	14/06	MT
AstraZeneca - Farxiga approved in the US for the treatment of paediatric type-2 diabetes	13/06	AQ

More news

Quotes 5-day view

Date	Price	Change
14/24/14	1.13	+5.61%
13/24/13	1.07	-2.73%
12/24/12	1.1	+5.77%
11/24/11	1.04	-7.96%
10/24/10	1.13	+1.80%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 08:51 pm IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC836J
ISIN	DE000PC836J8
Date issued	30/04/2024
Strike	15,000 p
Maturity	19/12/2025 (551 Days)
Parity	10 : 1
Emission price	0.59 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.16 €
Lowest since issue	0.81 €
Spread	0.01 €
Spread %	0.87%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company